RNAC
Selecta Biosciences Inc

7,725
Mkt Cap
$172.57M
Volume
106,532.00
52W High
$16.62
52W Low
$5.98
PE Ratio
-1.30
RNAC Fundamentals
Price
$6.51
Prev Close
$6.57
Open
$6.53
50D MA
$7.26
Beta
1.81
Avg. Volume
129,193.46
EPS (Annual)
-$5.02
P/B
-1.34
Rev/Employee
$37,293.33
$74.80
Loading...
Loading...
News
all
press releases
Cartesian Therapeutics' (RNAC) "Outperform" Rating Reiterated at Wedbush
Wedbush restated an "outperform" rating and issued a $38.00 price target on shares of Cartesian Therapeutics in a research report on Tuesday...
MarketBeat·11d ago
News Placeholder
More News
News Placeholder
Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from Needham & Company LLC
Needham & Company LLC reiterated a "buy" rating and issued a $42.00 price target on shares of Cartesian Therapeutics in a report on Monday...
MarketBeat·12d ago
News Placeholder
Cantor Fitzgerald Upgrades Cartesian Therapeutics (NASDAQ:RNAC) to Overweight
Cantor Fitzgerald raised Cartesian Therapeutics from a "neutral" rating to an "overweight" rating and set a $16.00 price target for the company in a research note on Monday...
MarketBeat·12d ago
News Placeholder
Insights into Cartesian Therapeutics Q4 Earnings
read more...
Benzinga·12d ago
News Placeholder
Cartesian Therapeutics (RNAC) to Release Earnings on Thursday
Cartesian Therapeutics (NASDAQ:RNAC) will be releasing earnings before the market opens on Thursday, March 12. (View Earnings Report at...
MarketBeat·16d ago
News Placeholder
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Rating of "Moderate Buy" by Brokerages
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five research firms that are currently covering the firm, Marketbeat.com...
MarketBeat·19d ago
News Placeholder
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have been given an average rating of "Moderate Buy" by the five ratings firms that are currently covering the firm...
MarketBeat·1mo ago
News Placeholder
Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?
Cartesian Therapeutics, Inc. (RNAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago
News Placeholder
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five research firms that are currently covering the firm...
MarketBeat·3mo ago
News Placeholder
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have received an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm...
MarketBeat·4mo ago
<
1
2
...
>

Latest RNAC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.